Every presentation at a pharmaceutical company of a drug development project, and, in the past 10 years, every grant application for public funds in the area of biomedical sciences, starts with a litany of diseases that may be treated if the proposed projects are supported and successful. In most, if not all, of these proposals the genetics of the affected population and the pharmacology of current and prospective treatment is a major component for consideration. In this sense, pharmacogenomics has always been part of decision-making and project selection in drug development. The practice of complementing epidemiologic, diagnostic and treatment-rate data with pharmacogenetics data was introduced in the 1950s, and the term pharmacogenetics was coined by Motulsky in 1957. 1 Motulsky wrote, 'Genetically controlled drug reactions not only are of practical significance, but may be considered pertinent models for demonstrating the interaction of heredity and environment in the pathogenesis of disease,' much in tune with Vogel's article in 1959 2 and Haldane's classic book: The Biochemistry of Genetics. 3 Now, 45 years later, after the completion of the Human Genome Project and the massive application of microarray and other molecular genetic techniques, this field of pharmacogenetics has been renamed, and partially refocused, as the growing field of pharmacogenomics. The current definition has been adopted by numerous government-sponsored workshops on both sides of the Atlantic, defining pharmacogenomics as 'the molecular study of genetic factors that determine drug efficacy and toxicity.' The emergent definition followed from, and was followed by, a flow of ideas, talent and capital (ca. $20 billion over the past 6 years) into the use of pharmacogenomics in clinical trials and in preclinical drug discovery. The impact of these efforts on drug discovery process and pipelines has been much discussed in terms of return on investment.
THE BROADER PICTURE
The political, social and economic consequences of pharmacogenomics, such as the genotyping of larger patient populations in major diseases are also being discussed, albeit too little. Academic society tends to regard pharmacogenomics as a 'MUST' for better or more effective drug development, but leaves the discussion of the methods and results of pharmacogenomics to the pharma industry, regulatory agencies, and to a lesser extent, academic researchers. Not withstanding the insightful, conscientious, balanced and courageous efforts of FDA and European regulatory agencies to spearhead discussions with the pharma industry on the use of pharmaco- Some of these discussions are aimed at establishing that the science is used properly, that biostatistics of enriched populations remain properly 'powered', and that not too many comparisons are made using the same populations-leading to a reduction of the power of the studies-as we see happen too often. This article will assume that these efforts to make the scientific foundations solid and robust will be successful and that science corrects itself where and when needed.
The issues of large-scale genotyping of populations, which the wider use of pharmacogenomics-based drug discovery and medicine will necessitate, are complex and affect the whole of society-and not just the pharmaceutical industry, regulatory bodies and patients. Many of the issues discussed here have been the subject of careful, foreward-thinking analysis by scientists, industry and academia alike, and their views form the basis of the start of a wider discussion encompassing the ethical, political, social and technological aspects of the use of pharmacogenomics. [6] [7] [8] [9] [10] [11] [12] [13] Genotyping of a whole nation, as was envisioned and currently ongoing in Iceland.
14 for the entire population of 290 000, has political risks. These were understood and carefully considered when the Icelandic parliament agreed to the De Code project. What if a major vulnerability for a microbial or chemical agent were more common in one ethnic group (here in one isolated nation)? In the extreme, it could become an obvious and exploitable threat of the development of a specific 'genocide weapon.' Luckily, even isolated populations are sufficiently outbred to make this risk small, although not zero, at the level of today's molecular genetics. In many countries elite forces, and sometimes the majority of entire armed forces, are recruited from a single ethnic group, which would make them potentially vulnerable if massive genotyping turns up some vulnerability. Individual leaders are now safeguarding with secrecy their own DNA to prevent predictions of disease, and treatment outcomes, etc, which could affect political stability.
One may claim that this is not new, that we have known for many years about HLA-subtype differences between races and their consequences in disease responses: massive genotyping of populations to predict safety and efficacy of agents will turn this knowledge from a blunt instrument into a sharp one. This trend to broaden genotypic knowledge about individuals in populations has to be carefully monitored at the political levels of society.
SOCIAL-ETHICAL ASPECTS
The broader ethical aspects of pharmacogenomics are only just being appreciated. Indeed, too few drugs are marketed today that require genotyping, although the clear coupling between the success of breast cancer treatment with herceptin and HER1, two genotypes provide a clear example in which genotyping is not only recommended but required for the commencement of treatment. 15, 16 This example of Herceptin use based on patient selection by genotyping is, however, not going to be representative of the ethical challenges of the wide use of pharmacogenomics because (1) breast cancer is a life-threatening disease that is socially and sympathetically recognized and (2) no discussion of allele frequency, etc, among ethnic groups has really surfaced as being significant or relevant. This will not be true for all diseases.
When similar requirements of diagnostic genotyping emerge for complex major diseases that do have ethnic or life-style components, much more ethical debate will occur. We should be already clearly cognizant that by making drugs tailored for specific genotypes, we shall in fact precipitate these societal developments.
The capacity and ability to choose populations for which we develop the new generation of safer and, hopefully, more efficacious drugs will meet significant, appropriate, and rightful resistance as the 'right to health' is embraced as universal. The focused development of drugs for a particular group of patients may not be socially or politically acceptable, unless the genotype is demonstrably evenly occurring across different ethnic and social groups. The scientific underpinnings of the projects (ie, clear coupling between genotype and drug response) are being taken for granted in this discussion, but this indeed is as yet unproven and must be fully explored and validated between pharmaceutical industry and regulatory agencies before it should become dogma.
Social consequences may replace the already known and terrible global consequences of the economic imperatives that companies must obey. Today, whole continents are written off as a potential market for which a Pharma company could develop drugs. With the genotyping of richer nations, such arguments may arise regarding some groups within the country. What should a government do if it turns out that a group that is genotypically defined, but because of its economical, political and/or social state is not judged as a promising market, and therefore no drugs-safe enough and efficacious enough-are developed for this group? Should the free market permit an Africa-like development in terms of tailoring drugs, and underwriting costs, for a specific population within the country?
THE PHARMACEUTICAL INDUSTRY DILEMMA There is great interest in increasing the chance that the safe and efficacious drugs which companies develop have a higher likelihood of reaching the market and staying there than is presently the case. The cost of projects is steadily rising, and development costs of $800 million-1.7 billion development cost for a major drug with expected sales of $1 billion/year is common. With this in mind, the Pharma industry is in a seemingly unrecognized or, at least, underappreciated dilemma. It wants to use the best science to predict treatment response, but also wants the drug to sell for $1 billion/year, as well as marketable to large patient groups. The marketing costs and trial costs are considerably higher than preclinical development costs. Pharmacogenomics promises better treatment response, and thus would justify a higher drug price, but only to the smaller patient groups-who genotypically qualify. Nevertheless, few calculated examples are available in terms of drug development cost and return on working capital: information required to split large therapeutic indications like antihypertensive therapy into 10 smaller ones based on genotyping.
Several large companies such as, for example, GSK, Roche-De Code, and others specifically look at cardiovascular risk-genotyping 13, 17 and thus may find good genotypically sound specific targets. However, it is not clear internally that major Pharmaceutical company leaderships are willing to or able to work on 10 times as many targets, and conduct 10 times as many clinical trials (of almost the same size as the nongenotypically based trial in an outbred general population and stratified selection calls for)-in exchange for a substantial reduction of the risk of failure in Phases 2 and 3 based on clinical trials conducted with enriched population. The industry works very hard on 'failing early' and cheaply on the use of biomarkers that may give some early indication of efficacy. But this does not mean that one wants smaller indications with resulting smaller markets. Economically-in terms of the drug development costone would need to significantly increase the success ratio from 10 NCE entering into clinical trials to produce one approved drug. Success would have to improve so that only three
NCEs would be needed for each approved drug. In addition, it is assumed that the pricing of these genotypically tailored drugs will be 2-3 times higher based on improved response and safety. How the marketing methods would have to change and whether General Practitioners or only specialists will prescribe genotypically tailored drugs are also looming unanswerable questions of great economical impact.
We will need many successful tailormade drug examples before the 150-year-old machine of 'Big Pharma' will be fully changed. Indeed, it is questionable if it is fully desirable that it should change. It is expected and understandable that many diagnostic companies which specialize in genotyping push for such development.
Some Biotech companies will predictably be successful with small indications that require genotypingand products of 100-300 m/year sales may be highly profitable to their cost structure. The success of such Biotech companies may force and/or induce big pharmaceutical corporations to adopt such strategies via acquisition or through direct competition with the Biotech companies.
If clinical trials reveal that a drug which was developed without regard to genotype is safer or more efficacious in a genotypically enriched group, 15, [17] [18] [19] [20] [21] than a drug that took genotype into consideration, there are no ethical issues to consider. It is a good scientific and medical practice to learn from the data at hand and to use it for safer and better treatment of the next patient. For the pharmaceutical companies, although the financial rewards may be different from the originally expected and projected ones, it is still better to restrict the use of a drug whose development, premarketing and marketing costs are already fully paid, than to drop it altogether as unsafe. (NB the heroic efforts by GSK to identify a set of SNPs that in a manner predict side effects of their AIDS drug Acabavir and thereby retain it in the clinic rather than withdraw it; this type of pharmacogenomics pays for the company and may pay for the new patients).
MAJOR SIMULTANEOUS LARGE CHANGES ARE REQUIRED
For the expanding use of pharmacogenomics in pharmaceutical company decision-making and drug development to become established practice, several parallel developments must take place in our society, of which the pharmaceutical industry itself is only one factor. Table 1 summarizes the changes that have to take place simultaneously at many levels of society to make the practice of 'individualized' or geno-
Legislative changes to protect genotype data are needed, in order to guarantee secrecy and enhance the willingness of patients to genotype themselves, and, thereby, reveal their susceptibilities to perhaps less socially accepted diseases than cancer, such as mental disease. Indeed, the US Senate vote in October 2003 on genetic integrity is a major step in the legislative arena. Our inability to predict disease onset, severity or treatment outcomewith the exception so far of a few cases in small studies-turns the genotype data of a patient into a blunt, nonscientific and potentially arbitrary instrument of discrimination in the hands of insurance companies, employers and others. Once the data are generated, it will be much harder to create legal protection when an insurance company subsequently requests the data whenever such data were generated. Such legislation needs to be watertight and bulletproof. It is too easy for companies to discriminate indirectly through elevated pricing and deepening discounts for the 'genotypically favored'. It must be regulated and preferably prevented, such that Insurance companies can request genotyping data or offer different rates to those who are willing to submit to genotyping.
Encryption to protect individuals has been well planned in Iceland in the DeCode project 22, 23 , and even if the encryption is imperfect and breaks, the Icelandic socialized medicine platform will take care of everyone independent of genetic vulnerability and of predicted, actual risk from such vulnerability data.
14 Such a 'guarantee' does not exist in countries where medical insurance is dominated by private companies.
Major changes are to take place at the drug company level: they need to be willing to split large indications with their potential $1 billion/year drugs, into smaller ones based on genotype, and, moreover, develop drugs that will benefit a haplotype specifically and with greater efficacy than today's nonhaplospecific drugs. The changes in strategic and marketing requirements, and in clinical trial strategies, will be profound once a large part of the companies' drug development projects are directed towards genotypically enriched groups of patients. Traditionally, the companies looked at what could be learned from a small group of patients in a familiar type of disease, in hopes that the lessons learned will enable them to make a drug for the much larger sporadic cases, and, with this in mind, the trials were almost always carried out in the large nonfamiliar case populations. This would change if the companies were able to make drugs so selective that they were only safe and efficacious in the genotypically specified group. While we have seen this as being possible for some therapeutic antibodies, for small molecule drugs, this may be a much taller order at our present level of knowledge. If, however, very specific drugs were to be made, then drug companies must seriously consider the potential for drug withdrawal from the entire population, if dangerous or fatal consequences follow from the prescriptions given to individuals outside the drug's intended patient population as defined by pharmacogenomics. 'Off-label' use, and tacit acknowledgement of it, may come to be revisited.
Thirdly, regulatory agencies in the US and Europe have thus far been on top of these scientific and industrial developments. While they can regulate the approval of drugs from trials adjusted to smaller 'genotypically enriched' populations, they cannot adequately regulate and control off-label use in clinical practice.
The industry tends to push for 'enriched populations' in order to improve the likelihood of showing efficacy, with, of course, maintained safety, while the regulatory agencies must put safety first-at least for nonlife-threatening diseases. Also, the biostatistics of powering studies for genotypically enriched populations are unclear (eg population size, allele frequency, etc, are changing), and the repetition of such studies in outbred populations is a must. Thus, trial size will not or should not be significantly reduced.
There are a growing number of excellent articles and reviews 7, 11 on the use of pharmacogenomics in the selection of clinical candidates from a pharmacotoxicological or toxicogenomic 15, 24 point of view, as well as on the use of pharmacogenomics in the design and execution of early and late phase clinical trials. 4, 17, 18, 20, 21 In addition, some authors have addressed the broader issue of the desirability, and potential risks, of stratifying patients for trials in order to enhance the likelihood of showing efficacy. The pros and cons will become clearer as clinical trials embrace more pharmacogenomic data, and as the data on SNPs, linkages and drug response phenotypes become available more broadly. These data will then mesh with results in real clinical practice where the robustness of coupling between genotype and drug response in patients, after chronic, repeated treatment, can be evaluated.
The primary risk is that we may not be able to restrict the later medical practice of extensive off-label use, thereby potentially endangering patients in the greater general population, who do not carry the genotype in which both safety and efficacy was established.
Huge changes are needed for a wider application of pharmacogenomics in drug development, and such changes are slow, costly and hard to predict in terms of social, political and even economic consequences. On the other hand, scientific trends continue with great momentum and the large investments fueling them are guaranteeing that the case for pharmacogenomics assumes an irresistible inevitability. But, as is customary in the industry as well as in medical practice, a cost/ benefit or risk/benefit analysis is worth carrying out. Some recent analysis on the promise of pharmacogenomics for drug development turned out to be sobering.
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PHARMACOGENOMICS CONTRIBU-TION TO DRUG DISCOVERY 2003
While examining the impact of pharmacogenomics in 2003, the most positive contribution of this field is found in the post-trial stratification of patients to enhance the safety of drugs where the gains are substantial for patients and companies alike. Trial design is also positively affected by pharmacogenomics (cf. Roses 13 ). Although the use of large-scale genotyping carried out on patient samples collected during trials is becoming an ethical and moral issue, it is, at the moment, not an issue legally. Currently, these samples are owned by the Pharmacogenomics in drug development T Bartfai companies, but do they truly own the data they may glean by examining massive number of SNPs? No matter how noble the company's cause might be, if there were no scientific hypotheses, agreed by others, independent from the company, then what is being looked at is likely to relate to the disease or to the drug response and would not be broader than that. Therefore, there should be some obligation for companies to disclose their findings without compromising their intellectual property rights.
In this article, we also attempt to take a snapshot of how pharmacogenomics has so far affected early drug discovery. (Effects of pharmacogenomics on postmarketing stages of the life of drugs have been mentioned above.) Within the preclinical drug discovery cascade, the different steps in drug discovery are affected by or have embraced pharmacogenomics methods to different extents (as listed in Table 2 ).
The bottlenecks in drug discovery vary with the therapeutic area. For example, it is considered that oncology, virology and endocrinology are rich, and psychiatry is relatively poor, in drug targets. There are, however, many more drug targets in oncology or in virology that involve, for example, protein-protein or protein-DNA interactions for which the industry's present chemical libraries have few hits to offer, and hence the starting points for medicinal chemists are thought to be limited. Consequently people, including the author, hoped that large-scale genotyping in diseases where animal models do not exist or have proven of limited validity (eg like mental diseases schizophrenia 18 and dementia) will help to provide new drug targets, and that such targets will provide completely new insights to the etiology and pathogenesis of these diseases. 25 In such a case, the targetpoor therapeutic areas would benefit most.
It was hoped that, in the context of selection and validation of drug targets, pharmacogenomics would mean a huge breakthrough. 13, 18, 26 This expectation by both Pharma companies and the public can be traced by the founding of projects, biotech companies, biotech-big pharma consortia (De Code, Celera, CuraGen, Avonex, Lexicon, HGS, Millenium etc) all projecting that new drug targets and, thus, hopefully, new drugs, will be discovered for large indications such as obesity, rheumatic arthritis and schizophrenia, etc.
In the area of target discovery, the present drug discovery pipelines have, however, little to show that is based directly on human pharmacogenomics: only one drug approved in 2001 and two in 2002 can be traced back to pharmacogenomic-derived targets (cf. FDA data). This, of course, in part reflects the long time-lines of drug development. This is in spite of there being very notable examples of scientific knowledge breakthroughs from linkage studies and positional cloning, such as the recognition of specific channelopathies and, thus, the identification of subtypes of ion channels associated with mostly single-gene, genetic diseases. There are other examples in inflammation, oncology and metabolic disease areas, yet one has to say that the majority of targets today addressed by pharma research projects come from the painstaking work on signaling pathways. The large number of human SNPs has so far seldom shown the way to a new drug target, but this may change as we learn about multigenic complex diseases (cf. Roses 27 ). Human linkage data have led to a new focus on pathways and thus indirectly to new targets. Notable examples in the area of central nervous system (CNS) drugs include the ApoE 3/4 effect on the onset of Alzheimer's disease, a now 10-year-old observation 28 that has been repeated in numerous studies, which has not provided drug targets but has produced very good ideas for research in the broader area. The more recent identification of neuregulin-1-schizophrenia linkage discovered in Iceland 29 and later confirmed in another population in Scotland 30 has resulted in renewed interest in the pathway for this tropic factor signaling. However, it seems clear that neuregulin-1, or even its receptor, is not yet embraced as a drug target. Common to these wellreplicated findings that the linkage studies point to proteins that participate in multiple cellular functions and thus possess several protein interactive partners through which they affect multiple signaling pathways. To the disappointment of researchers and investors alike these proteins themselves are not belonging to the favorite drug target categories of the Pharmaceutical Industry: enzymes, GPCRs, For those in target selection, it does not matter whether target identification and validation come from targeted null-mutation or random mutagenesis such as employed in the many forward mutagenesis programs around the world. It is the appearance or the unmasking of a robust phenotype associated with the mutation that will be decisive in the early drug development decision, not how the mutation has arisen, be it naturally, targeted, or random.
While toxicogenomics is one of the best-adopted aspects of pharmacogenomics in the whole drug development process it is surprising to find that CYP2D6 19 is not used in clinical practice to guide selection of drugs, although it is well documented that CYP2D6 metabolizes 50% of the 100 best-selling drugs in the USA and that there are numerous gene deletions, duplications, mutations, all substantially affecting drug metabolism and directly impacting on drug action and adverse reactions.
URGENCY OF WIDER ETHICAL DE-BATE ON PHARMACOGENOMICS IN DRUG DEVELOPMENT
Pharmacogenomics is here, and it is going to stay. Pharmacogenomics provides a useful contribution to the development of new drugs; both in diseases for which we have no medicines, and in other diseases, for the development of newer, safer and more efficacious drugs. This, hopefully, justifies the currently existing large financial investments, and will also justify the enormous efforts needed by many players in society to limit its potentially harmful uses outside of the narrower, well-regulated area of drug therapy.
To be more certain than we can be today of this development, we need a forum to watch the early steps of the ethical uses of the large-scale genotyping portion of pharmacogenomics. As outlined above, legislative and subsequent regulatory decisions and societal (insurance, employer) changes will be needed and, thus, the group overseeing these changes must reflect the political will of the countries involved, and have experts as their aids rather than having expert committees without a real chance of their views being adopted into public policy. The Icelandic example of parliamentary commission and expert panels has worked well and is recommended for adoption elsewhere. 9, 14 It is the duty of regulatory agencies and of academic scientists to request from government the formation of a body that will broadly represent the varied views and interests pharmacogenomics affects. Industry has rarely initiated regulatory moves.
The small-scale, individual and disease-related genotyping, meanwhile, is becoming part of the practice of modern medicine, to the clear benefit of everyone.
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